What percent of FDA scientists and committee members who are in charge of approving drugs have been part of the “revolving door?” And how do we know this is inherently bad? It may be, but I can also see how niche expertise would cause you to float between entities as appropriate.

Keep in mind 90% of drugs fail clinical trials. The situation cannot be THAT bad.